SpineThera Awarded $224,577 SBIR Phase I Grant from NIH

SpineThera, a privately held, pre-clinical stage pharmaceutical company, announced the award of a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Health.

"We are pleased to secure this non-dilutive funding from NIH that will help advance the development of our lead drug product candidate, a sustained-release injectable corticosteroid formulation that is being designed to meet the unique needs of epidural administration," said Jeff Missling, SpineThera's founder and CEO. "Our patent protected technology has the potential to significantly extend the duration of back pain relief from a single epidural injection compared to the generic steroids which are routinely used off-label today."

SpineThera was awarded $224,577 from the National Institute of Arthritis And Musculoskeletal And Skin Diseases (NIAMS) of the National Institutes of Health (NIH).